GSK plc Share Price

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 09:05:01 24/06/2024 pm IST 5-day change 1st Jan Change
1,608 GBX +0.59% Intraday chart for GSK plc +0.53% +10.92%

Financials

Sales 2024 * 3.17TCr 4.02TCr 3,35400Cr Sales 2025 * 3.36TCr 4.27TCr 3,56400Cr Capitalization 6.56TCr 8.32TCr 6,95100Cr
Net income 2024 * 553.6Cr 702.58Cr 59TCr Net income 2025 * 649.6Cr 824.41Cr 69TCr EV / Sales 2024 * 2.46 x
Net Debt 2024 * 1.21TCr 1.54TCr 1,28500Cr Net Debt 2025 * 864.21Cr 1.1TCr 92TCr EV / Sales 2025 * 2.21 x
P/E ratio 2024 *
11.8 x
P/E ratio 2025 *
10.1 x
Employees 70,212
Yield 2024 *
3.77%
Yield 2025 *
3.92%
Free-Float 94.53%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on GSK plc

1 day+0.59%
1 week+0.53%
Current month-8.94%
1 month-9.35%
3 months-4.64%
6 months+10.96%
Current year+10.92%
More quotes
1 week
1 575.00
Extreme 1575
1 629.00
1 month
1 575.00
Extreme 1575
1 787.50
Current year
1 453.20
Extreme 1453.2
1 823.50
1 year
1 302.60
Extreme 1302.6
1 823.50
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 01/10/01
Director of Finance/CFO 62 01/23/01
Compliance Officer - 01/95/01
Members of the board TitleAgeSince
Director of Finance/CFO 62 01/23/01
Chairman 66 01/19/01
Director/Board Member 62 01/18/01
More insiders
Date Price Change Volume
24/24/24 1,608 +0.59% 18,591,250
21/24/21 1,599 -1.17% 16,605,890
20/24/20 1,618 +0.09% 3,916,051
19/24/19 1,616 +0.28% 3,034,402
18/24/18 1,612 +0.75% 4,665,533

Delayed Quote London S.E., June 24, 2024 at 09:05 pm IST

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.08 GBP
Average target price
20.36 GBP
Spread / Average Target
+26.61%
Consensus
1st Jan change Capi.
+10.92% 8.32TCr
+52.70% 80TCr
+41.58% 63TCr
-4.86% 36TCr
+21.96% 34TCr
+11.47% 31TCr
+17.72% 25TCr
+4.46% 23TCr
+13.13% 22TCr
+10.46% 17TCr
Other Pharmaceuticals